Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
Haematologica · 29.02.2024 · 109 (7) · 2331-2336
DOI: 10.3324/haematol.2023.284635 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Haematologica, online erschienen am 29.02.2024. Verfasst von Fredrik H Schjesvold und 17 weiteren Autor:innen. Beteiligte Einrichtung: Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norwa…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Multiple Myeloma, Quality of Life. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. fredrikschjesvold@gmail.com.
- Department of Medicine I, Center for Medical Oncology and Hematology with Outpatient Department and Palliative Care, Wilhelminen Cancer Research Institute, Vienna.
- Bone Marrow Transplantation Unit and Department of Hematology, Evangelismos Hospital, Athens, Greece.
- Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
- University of Medicine and Pharmacy "Carol Davila", Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
- Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin.
Zitieren
APA
Schjesvold, F. H., Ludwig, H., Delimpasi, S., Robak, P., Coriu, D., Tomczak, W., Pour, L., Spicka, I., Dimopoulos, M. A., Masszi, T., Chernova, N. G., Sandberg, A., Thuresson, M., Norin, S., Bakker, N. A., Mateos, M. V., Richardson, P. G., & Sonneveld, P. (2024). Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica, 109(7), 2331-2336. https://doi.org/10.3324/haematol.2023.284635
Vancouver
Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, et al. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica. 2024;109(7):2331-2336. doi:10.3324/haematol.2023.284635
BibTeX
@article{Schjesvold2024,
author = {Schjesvold, Fredrik H and Ludwig, Heinz and Delimpasi, Sossana and Robak, Pawel and Coriu, Daniel and Tomczak, Waldemar and Pour, Ludek and Spicka, Ivan and Dimopoulos, Meletios-Athanasios and Masszi, Tamas and Chernova, Natalia G and Sandberg, Anna and Thuresson, Marcus and Norin, Stefan and Bakker, Nicolaas A and Mateos, Maria-Victoria and Richardson, Paul G and Sonneveld, Pieter},
title = {Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study},
journal = {Haematologica},
year = {2024},
volume = {109},
number = {7},
pages = {2331--2336},
doi = {10.3324/haematol.2023.284635}
}
EUVIMED